checkdown-arrowsearchshare

This site is intended for healthcare professionals outside the U.S.

The OTEZLA® International Website


close x

You are now leaving Otezla.net!


OTEZLA: Change the way
you treat psoriatic arthritis

BROAD AND SUSTAINED EFFICACY

  • The only oral treatment to deliver efficacy across the multiple clinical symptoms that define psoriatic arthritis1
    • Tender/swollen joints2,3
    • Dactylitis4
    • Enthesitis4
    • Axial symptoms5
    • Skin psoriasis6
    • Nail psoriasis7

PROVEN
LONG-TERM SAFETY

  • Well tolerated for up to 3 years8
  • Proven long-term safety profile8
  • No label-required laboratory monitoring9

EASE OF USE

  • Convenient, oral dosing9
  • Unique mechanism in psoriatic arthritis treatment—oral intracellular PDE4 inhibitor1,9

References: 1. Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26(9):2016-2029. 2. Kavanaugh A, Gladman DD, Gomez-Reino JJ, et al. Presented at: the Annual European Congress of Rheumatology EULAR 2016; 8–11 June 2016; London, UK. 2016. 3. Cutolo M, Mease PJ, Gladman D, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in tender and swollen joint counts in patients with psoriatic arthritis: results from three phase 3, randomized, controlled trials. Presented at: the 2013 ACR/ARHP Annual Meeting; October 26–30, 2013; San Diego, CA. Abstract 317. 4. . Gladman DD, Kavanaugh A, Adebajo AO, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (104-week) improvements in enthesitis and dactylitis in patients with psoriatic arthritis: pooled results from three phase III, randomized, controlled trials. Presented at: the 2015 ACR/ARHP Annual Meeting; November 7–11, 2015; San Francisco, CA. Abstract 2888. 5. Mease PJ, Marzo-Ortega H, Poder A, et al. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-term (52-Week) Improvements in BASDAI in Patients With Psoriatic Arthritis: Pooled Results From 3 Phase III, Randomized, Controlled Trials. Presented at: the Annual European Congress of Rheumatology EULAR 2016; 8–11 June 2016; London, UK. 6. Edwards CJ, Blanco FJ, Crowley J, et al. Efficacy of Long-term (104-Week) Treatment With Apremilast in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial and Open-Label Extension. Presented at: the 74th Annual Meeting of the American Academy of Dermatology; March 4-8, 2016; Washington, DC. 7. Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). JAAD. 2015;74(1):134–142. 8. Mease PJ, Gladman DD, Gomex-Reino JJ, et al. Long-term (156-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials. Presented at: the Annual European Congress of Rheumatology EULAR 2016; 8–11 June 2016; London, UK. 9. OTEZLA Summary of Product Characteristics. Stockley Park, Uxbridge, UK: Celgene Europe, Ltd; 2016.


Select an e-mail client to share

close x